An update on the application of nano-scaled carriers against fluconazole-resistant Candida species: nanostructured lipid carriers or solid lipid nanoparticles?

Document Type : Original Articles


1 Invasive Fungi Research Center, Mazandaran University of Medical Sciences, Sari, Iran

2 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

3 Department of Pharmaceutics, Mazandaran University of Medical Sciences, Sari, Iran

4 4 Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran

5 Department of Medical Laboratory Sciences, Sari Branch, Islamic Azad University, Sari, Iran

6 Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran


Background and Purpose: Encapsulation can lead to improved efficacy and safety of antifungal compounds. The attention of scientists has recently turned to biocompatible lipids as the carriers for the delivery of antifungal drugs, such as fluconazole. Although several research reports have already been published on fluconazole loaded solid lipid nanoparticles (FLZ-SLNs) and fluconazole loaded nanostructured lipid carriers (FLZ-NLCs), the possible advantages of NLCs over SLNs have not yet been fully established. Studies performed so far have given several contradictory results.
Materials and Methods: Both formulations of fluconazole were synthesized using probe ultrasonication method and the characteristics were analyzed. Antifungal susceptibility testing (AFST) was performed with FLZ, FLZ-SLNs, and FLZ-NLCs using CLSI document M60 against some common fluconazole-resistant Candida species.
Results: A significant decrease was observed in minimum inhibitory concentration values when both formulations were applied. Nonetheless, FLZ-NLCs were significantly more effective (p <0.05). However, three species groups were not statistically different in terms of the activity of FLZ-NLCs.
Conclusion: Based on the obtained results, FLZ-NLCs could reverse the azole-resistance phenomenon in the most common Candida species more effectively, as compared to FLZ-SLNs.


1. Lewis RE. Current concepts in antifungal pharmacology. New York: Mayo Clinic Proceedings; 2011.
2. Mut AM, Vlaia L, Coneac G, Olariu I, Vlaia V, Popoiu C, et al. Novel topical chitosan/hydroxypropylmethylcellulose-based hydrogels containing fluconazole and sucrose esters. Formulation, physicochemical characterization. vitro drug release and permeation. Farmacia. 2018; 66:59-69.
3. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 2010; 18(5): 195-204.
4. Polvi EJ, Li X, O’Meara TR, Leach MD, Cowen LE. Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies. Cell Mol Life Sci. 2015; 72(12):2261-87.
5. Mathy FX, Ntivunwa D, Verbeeck RK, Préat V. Fluconazole distribution in rat dermis following intravenous and topical application: a microdialysis study. J Pharm Sci. 2005; 94(4):770-80.
6. Rex JH, Rinaldi M, Pfaller M. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995; 39(1):1-8.
7. Pfaller M, Messer S, Hollis R, Jones R. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother. 2001; 45(10):2862-4.
8. Pandey R, Ahmad Z, Sharma S, Khuller G. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm. 2005; 301(1-2):268-76.
9. de Assis DN, Mosqueira VC, Vilela JM, Andrade MS, Cardoso VN. Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of 99mTechnetium-fluconazole nanocapsules. Int J Pharm. 2008; 349(1-2):152-60.
10. Maheshwari RG, Tekade RK, Sharma PA, Darwhekar G, Tyagi A, Patel RP, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J. 2012; 20(2):161-70.
11. Prajapati V, Jain A, Jain R, Sahu S, Kohli DV. Treatment of cutaneous candidiasis through fluconazole encapsulated cubosomes. Drug Deliv Transl Res. 2014; 4(5-6):400-8.
12. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006; 29(3-4):278-87.
13. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharmscitech. 2011; 12(1):62-76.
14. Kovacevic A, Savic S, Vuleta G, Müller R, Keck C. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm. 2011; 406(1-2):163-72.
15. Souza L, Silva E, Martins A, Mota M, Braga R, Lima E, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharma. 2011; 79(1):189-96.
16. Lan YB, Huang YZ, Qu F, Li JQ, Ma LJ, Yan J, Zhou JH. Time course of global gene expression alterations in Candida albicans during infection of HeLa cells. Bosnian J Basic Med Sci. 2017; 17(2):120-31.
17. Bose S, Du Y, Takhistov P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. Int J Pharm. 2013; 441(1-2):56-66.
18. Moazeni M, Kelidari HR, Saeedi M, Morteza-Semnani K, Nabili
M, Gohar AA, et al. Time to overcome fluconazole resistant Candida isolates: solid lipid nanoparticles as a novel antifungal drug delivery system. Colloids Surf B Biointerfaces. 2016; 142:400-7.
19. Wayne P. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. New York: CLSI document M59; 2018.
20. Wayne P. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M60. 2017. New York: Clinical and Laboratory Standards Institute; 2017.
21. Gohar AA, Badali H, Shokohi T, Nabili M, Amirrajab N, Moazeni M. Expression patterns of ABC transporter genes in fluconazole-resistant Candida glabrata. Mycopathologia. 2017; 182(3-4):273-84.
22. Nabili M, Shokohi T, Moazeni M, Khodavaisy S, Aliyali M, Badiee P, et al. High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue? J Med Microbiol. 2016; 65(6):468-75.
23. Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017; 216(suppl_3):S445-51.
24. Kelidari HR, Moazeni M, Babaei R, Saeedi M, Akbari J, Parkoohi PI, et al. Improved yeast delivery of fluconazole with a nanostructured lipid carrier system. Biomed Pharmacother. 2017; 89:83-8.
25. Souto E, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004; 278(1):71-7.
26. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3):165-96.
27. Hube B. Candida: comparative and functional genomics. Blackwells: Horizon Scientific Press; 2007.
28. Bianchin MD, Borowicz SM, da Rosa Monte Machado G, Pippi B, Stanisçuaski Guterres S, Raffin Pohlmann A, et al. Lipid core nanoparticles as a broad strategy to reverse fluconazole resistance in multiple Candida species. Colloids Surf B Biointerfaces. 2019; 175:523-9.
29. Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids. 2012; 165(4):454-61.